• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Intercept Pharmaceuticals

Loew
Pharma

Ipsen touts early launch results for liver disease drug Iqirvo

Ipsen’s Iqirvo is off to a solid launch as it battles with two other drugs to treat patients with the rare liver disease primary biliary cholangitis.
Kevin Dunleavy Apr 17, 2025 8:47am
Europe European Union EU European Commission EC

EU authorities revoke marketing nod for Advanz Pharma's Ocaliva

Dec 2, 2024 2:54pm
Image of a neon sign with the word no lit up next to an unlit yes

FDA shoots down Intercept's bid for full approval of Ocaliva

Nov 12, 2024 2:12pm
liver doctor liver disease

Intercept's Ocaliva nod in danger after negative FDA adcomm vote

Sep 16, 2024 10:40am
liver

Ocaliva's fate looks bleak after FDA releases new briefing docs

Sep 11, 2024 4:58pm
Gilead

FDA approves Gilead's Livdelzi for primary biliary cholangitis

Aug 14, 2024 3:29pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings